Clinical trials: HIV-1 Infections
HIV Infection
Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
The purpose of this study is to determine the safety of an immune response to an investigational HIV vaccine, ADMVA, at three different dosage levels, in adults who are not infected with HIV
- Trial name
- NCT00252148
- Testing
- ADMVA
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Covid19, HIV-1-infection
An Open-label Clinical Study of the Pharmacokinetics and Safety of Elsulfavirine, 200 mg Tablets, With Single and Multiple Oral Administration in Healthy Volunteers
An open-label clinical study of the pharmacokinetics and safety of Elsulfavirine, 200 mg tablets, with single and multiple oral administration in healthy volunteers.
- Trial name
- NCT05148754
- Testing
- Elsulfavirine
- Where
- Russia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Viriom
HIV-1-infection
A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health.
- Trial name
- NCT05414786
- Testing
- eOD-GT8 60mer mRNA Vaccine (100µg)
- Where
- 2 sites in Rwanda, South Africa
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV-1-infection, Opioid Use Disorder
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
The goal of this clinical trial is to determine the efficacy of Dolutegravir/Lamivudine (DTG/3TC), or "Dovato", in virally-suppressed (HIV-1 RNA < 200 copies/mL) individuals receiving opioid agonist therapy such as methadone…
- Trial name
- NCT06580873
- Testing
- DOVATO
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Saskatchewan Health Authority - Regina Area
HIV Infections
Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
This study will test the safety of and immune system response to a new HIV vaccine. The vaccine in this study is made from HIV DNA produced in a laboratory.
- Trial name
- NCT00069030
- Testing
- VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
- Where
- 7 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations
The factors that influence HIV disease progression are not well understood. While larger amounts of circulating virus (high 'viral loads') predict future adverse clinical events, many of the clinical factors responsible for high…
- Trial name
- NCT00001681
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
The Biology of HIV Transmission
The purpose of this study is to look at the amount of HIV in the blood, genital fluid, and saliva of the partners of patients with early HIV infection.
- Trial name
- NCT00001092
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
The effectiveness of a vaccine can be improved by using a "prime boost strategy" or by using an adjuvant. A prime boost strategy is the administration of one type of vaccine (the primer) followed by the administration of another…
- Trial name
- NCT00076037
- Testing
- HIV CTL MEP administered with RC529-SE adjuvant, GM-CSF
- Where
- 7 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine
To evaluate the safety of LFn-p24 administered at three different doses with Alhydrogel given intramuscularly To evaluate immune responses to LFn-p24 with Alhydrogel at three different doses given intramuscularly
- Trial name
- NCT00412477
- Testing
- HIV LFn-p24
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV Infections
A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
To evaluate the safety and immune response to 160 mcg HIV-1 recombinant envelope glycoprotein gp160. To evaluate the duration of antibody response and its relationship to dose and frequency of inoculation.
- Trial name
- NCT00000757
- Testing
- gp160 Vaccine (MicroGeneSys)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Peripheral Nervous System Disease
Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs
The purpose of this study is to find out what might increase nerve damage in people with HIV who have taken drugs for treatment of HIV disease.
- Trial name
- NCT00017771
- Where
- 18 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
The purpose of this study is to determine the safety of and immune response to an investigational HIV vaccine, VRC-HIVADV014-00-VP, with or without a second investigational HIV vaccine, VRC-HIVDNA016-00-VP, in HIV uninfected…
- Trial name
- NCT00124007
- Testing
- VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP
- Where
- 3 sites in Kenya, Rwanda
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.
- Trial name
- NCT00074581
- Testing
- Atazanavir, Didanosine, Efavirenz
- Where
- 17 sites in United States, Botswana and 7 more
- Volunteers
- 3,526 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hypertension, Dyslipidemias
Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US
This study has 3 aims. Aim 1: Identify social determinants of cardiometabolic health and determine facilitators and modifiable barriers in achieving treatment goals.
- Conditions
- Hypertension, Dyslipidemias, Type 2 Diabetes, HIV-1-infection
- Trial name
- NCT05129345
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Duke University
Bacterial Diseases, Other Mycoses
Reducing Vaginal Infections in Women
The purpose of this study is to see if taking medication once a month can help to decrease the risk of vaginal infections. Additionally, researchers will study whether personal habits, such as douching, bathing, and sexual…
- Conditions
- Bacterial Diseases, Other Mycoses, Sexually Transmitted Infection
- Trial name
- NCT00170430
- Testing
- Fluconazole, Metronizadole
- Where
- Kenya
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it.
- Trial name
- NCT00076063
- Testing
- ALVAC-HIV (vCP1452), LIPO-5
- Where
- 11 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects
The study is a randomized, Double-Blind, Placebo-Controlled study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics of SHR2150. will consist of 50 healthy subjects, 5 groups.
- Trial name
- NCT04802811
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
HIV Infections
Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults
The purpose of this study is to evaluate the safety and tolerability of an HIV-1 nef/tat/vif, env pDNA vaccine delivered with electroporation (EP), followed by a recombinant vesicular stomatitis virus (rVSV) HIV envC vaccine…
- Trial name
- NCT02654080
- Testing
- HIV-1 nef/tat/vif, env pDNA vaccine, rVSV HIV envC vaccine
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hiv
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good…
- Trial name
- NCT05001373
- Testing
- Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine
- Where
- 4 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Human Immunodeficiency Virus Type 1 (HIV-1), HIV Infections
Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir, 300/100 mg once daily (QD), in healthy participants…
- Trial name
- NCT00833482
- Testing
- Voriconazole, Atazanavir, Ritonavir
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb